Home › Funds › Ikarian Capital, LLC › CTNM
Ikarian Capital, LLC position in CTNM
CONTINEUM THERAPEUTICS INC CL A · Health Care
Ikarian Capital, LLC reported holding 807,874 shares of CTNM (CONTINEUM THERAPEUTICS INC CL A) in its Q2 2026 13F filing — a position valued at US$13.2M, representing 2.13% of its reported portfolio and ranking #11 among its reported holdings. Ikarian Capital, LLC has disclosed CTNM holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's CTNM position evolved
Ikarian Capital, LLC first disclosed a stake in CTNM in Q4 2025 at 282,874 shares (US$3.2M). The position peaked in Q2 2026 at 807,874 shares, worth US$13.2M. Across 3 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 807,874 shares valued at US$13.2M. Notable position changes include a 186% increase in Q1 2026 (shares rose 25% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 282.87K | $3.23M | New |
| Q1 2026 | 807.87K | $10.55M | Add |
| Q2 2026 | 807.87K | $13.24M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTNM and 13F data
CTNM (CONTINEUM THERAPEUTICS INC CL A) is a Health Care company. 63 other funds we track also report a position in CTNM — the largest reported positions include MONTANOVA CAPITAL, LLC (US$46.6M), JOHNSON & JOHNSON (US$32.4M), GREAT POINT PARTNERS LLC (US$15.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTNM
- MONTANOVA CAPITAL, LLC 2.84M sh · $46.57M · Q2 2026
- JOHNSON & JOHNSON 1.98M sh · $32.44M · Q2 2026
- GREAT POINT PARTNERS LLC 921.48K sh · $15.10M · Q2 2026
- SECTORAL ASSET MANAGEMENT INC 727.59K sh · $11.93M · Q2 2026
- Hillhouse Capital (HHLR Advisors) 669.34K sh · $10.97M · Q2 2026
- Versant Venture Management, LLC 542.63K sh · $8.89M · Q2 2026
- Red Tree Management, LLC 638.16K sh · $8.56M · Q3 2026
- Boxer Capital Management, LLC 494.00K sh · $8.10M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 296.13K sh · $4.85M · Q2 2026
- Squadron Capital Management LLC 260.00K sh · $4.26M · Q2 2026
- Ishara Investments LP 205.00K sh · $3.36M · Q2 2026
- Casdin Capital 148.33K sh · $2.43M · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held CTNM?
Ikarian Capital, LLC has disclosed CTNM holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Ikarian Capital, LLC's current position in CTNM?
As of Q2 2026, Ikarian Capital, LLC holds 807.87K shares of CTNM (CONTINEUM THERAPEUTICS INC CL A), valued at $13.24M, representing 2.13% of its reported portfolio and ranking #11.
Has Ikarian Capital, LLC been buying or selling CTNM?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC held unchanged its position in CTNM. The position peaked in Q2 2026 at 807.87K shares.
Which other funds hold CTNM?
Other major institutional holders of CTNM include MONTANOVA CAPITAL, LLC, JOHNSON & JOHNSON, GREAT POINT PARTNERS LLC, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.